Tag Archives: checkbox

Indexing Pioneer Vanguard Skeptical Of Smart Beta

Vanguard revolutionized investing with its low-cost, passive indexing products. But after the TMT (tech, media, and telecom) blowup of 2000-2002, when cap-weighted indexes became overstuffed with overvalued dot-coms, critics began maligning cap-weighted index funds as “dumb beta.” The alternative, in their view, was to weight stocks according to factors other than market cap – so-called “smart beta.” Smart-beta strategies have been hailed as the “new paradigm” in passive, index-based investing. But Vanguard, the indexing pioneer, disagrees: The firm’s Don Bennyhoff, Fran Kinniry, Todd Schlanger, and Paul Chin – authors of an August 2015 white paper titled ” An Evaluation of smart beta and other rules-based active strategies ” – insist that smart-beta strategies are in fact active strategies, and that market cap is still the best basis to weight the components of an index. How Active is Smart Beta? In Vanguard’s view, smart-beta strategies should be considered “rules-based active strategies,” by definition , since their security-selection and -weighting methodologies can produce “meaningful security-level deviations” – i.e., “tracking error” – versus a broad cap-weighted index. In the August 2015 white paper, Mr. Bennyhoff and his co-authors looked at the “active share” of smart beta ETFs and index funds. “Active share” is a measure of how much an index’s holdings deviate from a cap-weighted baseline, which in this case was the Russell 3000 – an index of the 3000 largest U.S. stocks, including the mid-to large-cap Russell 1000 and the small-cap Russell 2000: Source: Vanguard. All data as of December 31, 2014. In general, the more stocks in the index or portfolio, the less the “active share.” Smart-beta ETFs and funds had “active share” that ranged from a bit less than 30% to roughly 60%, generally much more than cap-weighted indexes, but less than “traditional, actively managed equity funds.” Smart-beta strategies also had less “active share” than ETFs focused on specific risk factors like value, momentum, and size – and its exposure to these factors that provides much of smart beta’s appeal, in Vanguard’s analysis. Which Factors and When? Vanguard admits that the performance of alternatively weighted indexes has been “compelling” over time. For instance, the alternative FTSE RAFI Developed Index returned an annualized 7.2% from 2000 through 2014, with a Sharpe ratio of 0.42. The cap-weighted FTSE Developed Index, by contrast, returned just 4.2% per year with a Sharpe ratio of 0.26. This relationship holds for most regions, too. But particular risk factors fall into and out of favor, and as a result, the performance of smart-beta strategies – relative to the broad market – has deviated substantially over time. Should investors only concern themselves with certain factors, such as dividends, cash flow, book value, sales, and volatility? Or should they consider all factors, which are too numerous to list? Vanguard says market cap-weighting captures all of these factors through the market-pricing mechanism – a compelling argument. Taking the Gloves Off Near the end of the white paper, Bennyhoff et al. take off their gloves: Smart beta doesn’t represent a “new paradigm” of indexing nor a “smarter” way to invest. The strategies’ excess returns can partly – in some cases largely – be attributed to “time-varying factor exposures,” which make smart-beta strategies effectively active and not passive. “We found little evidence that such smart-beta strategies have been able to capture any security-level mispricings in a systematic and meaningful way,” the authors wrote. An index of securities is supposed to represent “the risk-and-reward attributes of a market” or segment thereof. In Vanguard’s view, market-cap-weighting isn’t broken, and therefore isn’t in need of fixing. For more information, download a pdf copy of the white paper . Jason Seagraves contributed to this article.

AlphaCentric Converts Hedge Fund Into New Managed Futures Mutual Fund

Managed futures funds provide investors with exposure to commodities, currencies, stocks, and bonds by investing in a range of securities, including futures, forwards, swaps and ETFs. Due to the trend following, long/short nature of their investment strategies, these funds have very low correlation to traditional asset classes. As markets continue to be volatile and correlations between asset classes continue to increase, managed future funds are gaining more and more interest. In fact, this category of funds has been the most popular single-strategy category of liquid alternative funds over the past year, pulling in $8.5 billion of assets over the twelve month period ending November 30, 2015, according to data from Morningstar. New AlphaCentric Fund While managed futures funds were available exclusively to high-net worth individuals and institutions in the past, today there more than 50 managed futures funds available as ’40 Act mutual funds, and on December 18, AlphaCentric and Integrated Managed Futures Corp (“IMFC”) added another to the growing roster: the AlphaCentric/IMFC Managed Futures Strategy Fund (MUTF: IMXAX ). Sub-advised by IMFC, the new fund differentiates itself from its peers by pursuing its investment objective of capital appreciation through IMFC’s proprietary investment program, which attempts to identify investment opportunities with limited downside and potentially large rewards. This investment program removes subjectivity and human emotion from the day-to-day decision-making process. The fund’s assets are allocated across asset classes using IMFC’s multi-factor models, which consider momentum, yield, value, relative buying power of different currencies, commodity cost of production and supply/demand statistics, price-to-earnings and -book ratios, the difference in yield between issuers or financial instruments, and more. The fund also maintains large cash positions as part of its investment strategy. Fund Details The AlphaCentric/IMFC Managed Futures Strategy Fund is available in three classes: A ( IMXAX ), C (MUTF: IMXCX ), and I (MUTF: IMXIX ). The Class I shares have been created through the conversion of a hedge fund (the Attain IMFC Macro Fund LLC) and will take on the performance track record of that fund dating back to March 10, 2014. The investment management fee for all shares of the fund is 1.75%, and the respective net-expense ratios are 2.24%, 2.99%, and 1.99%. The minimum initial investment for all three share classes is $2,500. Integrated Managed Futures Corp. will serve as the sub-advisor to the fund. Roland Austrup, Robert Koloshuk, and John Lukovich are listed in the fund’s prospectus as its portfolio managers. For more information, view a copy of the fund’s prospectus . Jason Seagraves contributed to this article.

What Does 2016 Hold In Store For Pharma ETFs

The pharma sector has been in the middle of a controversy, with questions being raised about the high prices of drugs. Democratic presidential frontrunner Hillary Clinton’s “price gouging” tweet triggered a slide in healthcare stocks in September. While there have always been concerns regarding the pricing and affordability of prescription drugs, the issue is back in focus following a 5000% price hike implemented by Turing Pharmaceuticals for Daraprim (pyrimethamine) that was approved by the FDA way back in 1953. (Read: 16 Bold ETF Predictions for 2016 ) Other companies like Valeant (NYSE: VRX ) are also under review for significantly hiking the prices of acquired drugs. Irrespective of who wins the presidential race, drug pricing will remain a topic of discussion among policymakers, the media and the general public. Meanwhile, mergers, acquisitions and deals continue to take center stage in the pharma sector. While 2014 turned out to be one of the most active years in the pharma sector where mergers and acquisitions (M&As) and licensing agreements are concerned, the trend continued this year as well. Small bolt-on acquisitions, in-licensing activities and collaborations for the development of pipeline candidates will also continue especially in therapeutic areas like central nervous system disorders, diabetes and immunology/inflammation. The hepatitis C virus market is also attracting a lot of attention. (Read: Top Sectors of 2016 and Their Leading ETFs ) Another lucrative area is immuno-oncology as these therapies have the potential to change the treatment paradigm for cancer — they basically use the natural capability of the patient’s own immune system to fight the cancer. Major players in this field include Bristol-Myers (NYSE: BMY ), AstraZeneca (NYSE: AZN ), Merck (NYSE: MRK ) and Roche. Deals targeting immuno-oncology are being inked by companies like Pfizer (NYSE: PFE ), Merck KGaA ( OTCPK:MKGAY ), Bristol-Myers, AstraZeneca and Incyte (NASDAQ: INCY ). Another trend being witnessed is the divestment of non-core business segments. Companies like Pfizer, UCB ( OTCPK:UCBJY ), Novartis (NYSE: NVS ), Glaxo (NYSE: GSK ) and AstraZeneca have all been a part of this trend. The monetization of non-core assets allows these companies to focus on their areas of expertise. Restructuring activities are also gaining momentum as large pharma companies are looking to cut costs and streamline their operations. Most of these companies are re-evaluating their pipelines and discontinuing programs which do not have a favorable risk-benefit profile. Swapping of businesses is another activity that could pick pace in 2016. Biosimilars are also a focus area. Pfizer’s acquisition of Hospira gives it a strong position in the biosimilars market. Companies like Merck and Novartis are involved in the development of biosimilars as well – in fact, Novartis’ Sandoz was the first company to launch a biosimilar in the U.S. New products are steadily gaining traction and contributing significantly to sales and so far in 2015, the FDA has approved 43 new molecular entities (NMEs) and biological products. Some of the important new product approvals this year include Vertex’s cystic fibrosis treatment, Orkambi, Pfizer’s cancer treatment, Ibrance, Novartis’ psoriasis treatment, Cosentyx, PCSK9 inhibitors – Amgen’s (NASDAQ: AMGN ) Repatha and Sanofi (NYSE: SNY )/Regeneron’s (NASDAQ: REGN ) Praluent, Roche’s advanced melanoma treatment, Cotellic and Gilead’s (NASDAQ: GILD ) Genvoya (HIV). Pharma ETFs in Focus Highlighted below are some pharma ETFs – ETFs present a low-cost and convenient way to get a diversified exposure to the sector. PowerShares Dynamic Pharmaceuticals Portfolio ETF (NYSEARCA: PJP ) PJP, launched in Jun 2005 by Invesco PowerShares, tracks the Dynamic Pharmaceuticals Intellidex Index. The fund covers health care stocks. The top 3 holdings include Bristol-Myers Squibb (5.22%), Eli Lilly & Co. (NYSE: LLY ) (5.16%) and Johnson & Johnson (NYSE: JNJ ) (5.13%). The total assets of the fund as of Dec 15, 2015 were $1,691.5 million representing 23 holdings. The fund’s expense ratio is 0.56% while dividend yield is 0.47%. The trading volume is roughly 135,985 shares per day. SPDR S&P Pharmaceuticals ETF (NYSEARCA: XPH ) XPH, launched in Jun 2006, tracks the S&P Pharmaceuticals Select Industry Index. This ETF primarily covers pharma stocks (99.39%) with the top 3 holdings being Intra-Cellular Therapies, Inc. ( OTCQB:ITCI ) (4.84%), Nektar Therapeutics (NASDAQ: NKTR ) (3.69%), and Bristol-Myers Squibb (3.44%). Total assets as of Dec 15, 2015 were $695.6 million representing 41 holdings. The fund’s expense ratio is 0.35% and dividend yield is 0.71%. The trading volume is roughly 65,529 shares per day. iShares U.S. Pharmaceuticals ETF (NYSEARCA: IHE ) IHE, launched in May 2006, seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index. The fund mainly consists of pharma companies (87%). Biotech companies account for about 10.6% of the fund. The top 3 holdings of this fund are Johnson & Johnson (10.79%), Pfizer (8.70%) and Bristol-Myers Squibb (7.84%). The total assets of the fund as of Dec 16, 2015 were $890.45 million representing 43 holdings. The fund’s expense ratio is 0.45% with the dividend yield being 0.89%. The trading volume is roughly 28,951 shares per day. Market Vectors Pharmaceutical ETF (NYSEARCA: PPH ) PPH was launched in Dec 2011 and tracks the Market Vectors U.S. Listed Pharmaceutical 25 Index. The top 3 holdings of this fund are large-cap pharma companies – Johnson & Johnson (7.97%), Novartis (7.02%) and Bristol-Myers Squibb (5.55%). The total assets as of Dec 16, 2015 were $335.9 million representing 26 holdings. While the expense ratio is 0.35%, dividend yield is 2.04%. The trading volume is roughly 72,694 shares per day. Conclusion While EU austerity measures, negative currency impact and pricing pressure remain headwinds, the pharma industry is out of the worst of its genericization phase. Many companies, which had faced generic headwinds in the last couple of years, should continue to see a sustained improvement in results this year. Cost-cutting, downsizing, emerging markets and new products should support growth. Increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector. Link to the original article on Zacks.com